You are here: Home » Economy & Policy » News
Business Standard

Drug regulatory infra gets Rs 1,750 cr

The money will be spent to set up testing laboratories and a training academy for regulatory and testing officials, among other things

BS Reporter  |  New Delhi 

Image via Shutterstock

With rising instances of quality scrutiny faced by Indian pharmaceutical companies in foreign markets, the government on Wednesday okayed Rs 1,750 crore to strengthen the drug regulatory system.

The money will be spent to set up testing laboratories and a training academy for regulatory and testing officials, among other things.

The decision by the Cabinet Committee on Economic Affairs says Rs 900 crore will be used to strengthen the central structures and Rs 850 crore made available to state governments. Much of state-level drug regulatory infrastructure lacks upgradation due to lack of funds.

Provision has been made for additional equipment and personnel in existing testing laboratories, setting up of new labs for testing drugs, medical devices and cosmetics, making mobile drug testing laboratories available, hiring of additional personnel for regulatory structures, including for new and emerging areas such as stem cells, regenerative medicine, biologicals and medical devices, in addition to drugs.

The upgrading will also introduce e-governance and information technology-enabled services, and setting up a training academy for regulatory and drug testing officials, of central and state governments.

India is one of the largest makers of drugs and exports pharmaceutical products to about 200 countries. Facilities of top companies like Sun and Lupin have been facing regulatory scrutiny by the Food and Drug Administration in the US, the largest export market. Recently, the European Union banned sale of pharma products tested at the GVK Biosciences facility in Hyderabad.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, August 13 2015. 00:24 IST